Navigation Links
Epeius Biotechnologies' Rexin-G Receives FDA Fast Track Designation for the Treatment of Pancreatic Cancer
Date:6/17/2009

SAN MARINO, Calif., June 17 /PRNewswire/ -- Epeius Biotechnologies (www.epeiusbiotech.com) announced today that its lead product, Rexin-G, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for use as a second-line treatment for advanced or metastatic pancreatic cancer. The FDA Fast Track program, like Priority Review and Accelerated Approval, was implemented to facilitate the development and expedite the review of potentially important new drugs. The Fast Track Product designation, in particular, is granted following a critical evaluation of the "seriousness" or life-threatening nature of the unmet medical need, namely pancreatic cancer, and the potential of Rexin-G and its progressive clinical development to address this unmet need.

"This is an excellent affirmation of all that we have worked for," says Dr. Erlinda Maria Gordon, Medical Director of Epeius Biotechnologies, "and an important validation of our medical mission." Indeed, Rexin-G is the first in an entirely new class of targeted anti-cancer agents, with a sophistication that goes well beyond a simplistic antibody. Rexin-G is the flagship of tumor-targeted genetic medicine: "smart," "stealth," "selective" and "potent" nano-medicine that not only seeks out and accumulates in cancerous lesions that have spread throughout the body, but delivers a tumor-killing designer gene where it is needed most, selectively destroying tumor cells and their attendant blood supply, while sparing normal cells and healthy tissues. As presented at the 2009 ASCO G.I. Symposium, "Rexin-G Shrinks Metastatic Tumors and Triples Survival Time in Chemotherapy-Resistant Pancreatic Cancer," documenting survival benefits, without toxicity, as monotherapy, when all else fails.

The FDA's timely decision to grant Rexin-G Fast Track Product Designation is not only validating in terms of the
'/>"/>

SOURCE Epeius Biotechnologies
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Therapure Biopharma Inc. and LFB Biotechnologies Announce Development Services Contract for New Therapeutic Protein
2. Millennium Biotechnologies Reports Strong Third Quarter Revenue and Financial Results
3. Ezra Van Gelder Joins Microchip Biotechnologies as Executive Vice President R&D
4. Veteran of the Beverage Industry, Ken Sadowsky, Joins Millennium Biotechnologies Board of Directors
5. MDS Analytical Technologies Acquires Blueshift Biotechnologies
6. Millennium Biotechnologies Inc. Signs Five Year $20,000,000 Purchase Agreement with Provider Services Inc. of Cleveland, Ohio
7. VaxGen and Raven biotechnologies Announce Signing of Definitive Merger Agreement
8. Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma: Phase I/II and Phase II Studies, ASCO 2009
9. FDA Approves the Opening of a Phase II Registration Protocol Using REXIN-G(R) for Osteosarcoma in California U.S.A.
10. STAAR Surgical Receives Japanese Clearance for the KS-Ni Preloaded IOL Injector System
11. Herzing University, Minneapolis Receives Board of Nursing Approval
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... Like nearly every other form of surgery, it ... made more effective and less intrusive and painful. Leading these advances in the ... Dr. Loria currently stands as the only doctor in the United States who is ...
(Date:7/31/2015)... ... July 31, 2015 , ... Florida Hospital Tampa ... that was developed for targeted delivery of fluids to selected sites in the ... Florida Hospital Tampa with the device that provides direct, local delivery of chemotherapy ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... announce that their latest designer handbag line will be named for Madeline Stuart, ... sensation as the first globally recognized model with Down syndrome, gracing the front ...
(Date:7/31/2015)... ... July 31, 2015 , ... According to WFLA on July ... heroin use and eventual overdoses. Thricefold deaths have held steady over the last “couple ... the Sarasota heroin epidemic, which was spurred by the crackdown of prescription painkillers. Many ...
(Date:7/31/2015)... ... 31, 2015 , ... New Energy Works Timberframers invites the public to join ... 15th, 2015 from 9am – 12pm. Timber frame raisings are special, celebrating ... community as the culmination of months of effort, planning, fundraising, and dreaming takes shape. ...
Breaking Medicine News(10 mins):Health News:Loria Medical Penile Enlargement Center to Expand, Offering Practice Partnership to Doctors 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4Health News:everMaya to Launch Madeline Stuart Handbag Line 2Health News:everMaya to Launch Madeline Stuart Handbag Line 3Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 3Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 2Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 3
... , Salad Bar to Be Donated to ... , , WASHINGTON, Aug. 19 The ... bar at its Fresh Festival event, September 9, in the Cannon House ... salad bar, stocked with fresh fruits and vegetables, will underscore the need ...
... , , NEW YORK, Aug. ... point-of-care digital signage network into major U.S. markets, including Detroit, Miami, ... demand for HMN,s services by healthcare providers and advertisers. Installations in ... markets is slated for the second half of 2009. HMN,s largest ...
... experts say , WEDNESDAY, Aug. 19 (HealthDay ... with the drug letrozole (Femara) increases survival after surgery ... confirms. , Both letrozole and tamoxifen have been used ... with hormone receptor-positive cancer, but whether one drug is ...
... , , , ... and BRISBANE, Calif., Aug. 19 Roche (SIX: ROG.VX; RO.S, OTCQX: ... that the first patient has been dosed in a Phase 2b ... in combination with PEGASYS(R) (pegylated interferon alfa-2a) and COPEGUS(R) (ribavirin). ...
... (August 19, 2009) Using a novel robot-assisted endoscopic ... of Medicine in Seoul, Korea, has successfully treated 200 ... which has several technical and cosmetic benefits that the ... the August issue of the Journal of the ...
... paraffin, suggest beeswax instead , WEDNESDAY, Aug. 19 (HealthDay ... ambiance, fragrance and light, may also contribute to air ... made from petroleum, are a source of known human ... to be presented Wednesday at the American Chemical Society,s ...
Cached Medicine News:Health News:United Fresh to Feature Salad Bar at Capitol Hill Event to Advocate National School Salad Bar Policy 2Health News:United Fresh to Feature Salad Bar at Capitol Hill Event to Advocate National School Salad Bar Policy 3Health News:Health Media Network Expands to New Markets 2Health News:Newer Drug Beats Tamoxifen for Older Breast Cancer Patients 2Health News:Newer Drug Beats Tamoxifen for Older Breast Cancer Patients 3Health News:Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C 2Health News:Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C 3Health News:Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C 4Health News:Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C 5Health News:Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C 6Health News:Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C 7Health News:Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C 8Health News:Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C 9Health News:Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C 10Health News:New robot-assisted surgical method found successful for treatment of thyroid cancer 2
(Date:7/30/2015)... CHAGRIN FALLS, Ohio , July 30, 2015 /PRNewswire/ ... in his OMTEC® 2015 keynote address last month that ... business models in order to gain the efficiencies—and develop ... future. Dr. Barsoum,s comments were preceded by ... Tornier, avid entrepreneur and OMTEC moderator, who stressed that ...
(Date:7/30/2015)... , July 30, 2015 ... research report with market overview, trends, DRO ... porter analysis, recent developments, competitive scenario and ... Industry Insight: Biosensors Market Development and Demand ... http://photos.prnewswire.com/prnh/20150727/756778 ) Explore more ...
(Date:7/30/2015)... 2015 Vermillion, Inc. (VRML), a ... announced today it will report its second ... close on Thursday, August 13, 2015, followed ... at 4:30pm Eastern.Conference Call and Webcast:  ... Pacific  Domestic: , 888-430-8691International: ...
Breaking Medicine Technology:Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 3Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 4Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 5
... Analysis of SPIRIT II and SPIRIT III Data Confirms Patients ... Death, a Heart Attack or a ... TAXUS(R) at Two Years, WASHINGTON, Oct. 13 Data ... randomized clinical,trials demonstrated that the XIENCE V(TM) Everolimus Eluting Coronary ...
... Class, of Stent with Polyzene(R)-F Surface ... for Long-Term,Dual Antiplatelet Therapy, WASHINGTON, ... today,s,"Innovative Devices and Futuristic Therapies" session ... (TCT) scientific,symposium, sponsored by the Cardiovascular ...
Cached Medicine Technology:Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years 2Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years 3Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years 4Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years 512-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions 212-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions 312-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: